UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 642

Sortiert nach

Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical Relevance

The AAPS journal, 2012-03, Vol.14 (1), p.119-132

Joerger, Markus

2012

Volltextzugriff (PDF)

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies

International journal of cancer, 2017-10, Vol.141 (7), p.1286-1294

2017

Volltextzugriff (PDF)

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

Clinical pharmacology and therapeutics, 2019-03, Vol.105 (3), p.598-613

2019

Volltextzugriff (PDF)

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity

International journal of cancer, 2015-02, Vol.136 (3), p.730-739

2015

Volltextzugriff (PDF)

Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors

Frontiers in oncology, 2020-11, Vol.10, p.581217-581217

2020

Volltextzugriff (PDF)

Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer

Oncoimmunology, 2021-01, Vol.10 (1), p.1988403-1988403

2021

Volltextzugriff (PDF)

Non-pharmaceutical interventions to optimize cancer immunotherapy

Oncoimmunology, 2023-12, Vol.12 (1), p.2255459-2255459

2023

Volltextzugriff (PDF)

Cancer chemotherapy: targeting folic acid synthesis

Cancer management and research, 2010-11, Vol.2 (default), p.293-301

2010

Volltextzugriff (PDF)

Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA, 2019-04, Vol.27 (4), p.1182-1188

2019

Volltextzugriff (PDF)

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e004024

2022

Volltextzugriff (PDF)

Treatment regimens of classical and newer taxanes

Cancer Chemotherapy and Pharmacology, 2016-02, Vol.77 (2), p.221-233

Joerger, Markus

2016

Volltextzugriff (PDF)

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

Exploration of targeted anti-tumor therapy, 2022-01, Vol.3 (1), p.27-36

2022

Volltextzugriff (PDF)

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

Haematologica (Roma), 2016-03, Vol.101 (3), p.346

2016

Volltextzugriff (PDF)

C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework

Cancers, 2023-11, Vol.15 (22), p.5429

2023

Volltextzugriff (PDF)

Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen

Frontiers in pharmacology, 2020-03, Vol.11, p.283

2020

Volltextzugriff (PDF)

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

Journal of translational medicine, 2017-03, Vol.15 (1), p.66-66, Article 66

2017

Volltextzugriff (PDF)

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-04, Vol.27 (12), p.2038-2045

2009

Volltextzugriff (PDF)

A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients

CPT: pharmacometrics and systems pharmacology, 2023-11, Vol.12 (11), p.1714-1725

2023

Volltextzugriff (PDF)

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (11), p.e007784

2023

Volltextzugriff (PDF)

Metabolism of the taxanes including nab-paclitaxel

Expert opinion on drug metabolism & toxicology, 2015-05, Vol.11 (5), p.691-702

Joerger, Markus

2015

Volltextzugriff (PDF)

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Journal for immunotherapy of cancer, 2019-07, Vol.7 (1), p.192-11, Article 192

2019

Volltextzugriff (PDF)

Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

Journal of clinical oncology, 2004-10, Vol.22 (20), p.4157-4164

2004

Volltextzugriff (PDF)

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (11), p.e007353

2023

Volltextzugriff (PDF)

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.50-50, Article 50

2019

Volltextzugriff (PDF)

1 – 25 von 642

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(194)
Mit Volltextzugriff
(598)

Publikationsform

Buchkapitel
(423)
Artikel
(184)
Bücher
(34)
Berichte
(1)

Sprache

Deutsch
(448)
Englisch
(205)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(144)
Life Sciences & Biomedicine
(142)
Humans
(110)
Oncology
(86)
Female
(58)
Male
(46)
Pharmacology & Pharmacy
(46)
Middle Aged
(44)
Grammar, Syntax, Linguistic Structure
(41)
Language & Linguistics
(41)
Usage & Grammar Guides
(41)
Aged
(37)
Adult
(36)
Pharmacokinetics
(30)
Cancer
(27)
Patients
(27)
Tumors
(26)
Chemotherapy
(23)
Prognosis
(23)
Lung Cancer
(22)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical Relevance

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy

Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early‐onset fluoropyrimidine toxicity

Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors

Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer

Non-pharmaceutical interventions to optimize cancer immunotherapy

Cancer chemotherapy: targeting folic acid synthesis

Vitamin C demand is increased after total knee arthroplasty: a double-blind placebo-controlled-randomized study

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

Treatment regimens of classical and newer taxanes

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)

C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework

Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

Randomized Phase II and Pharmacogenetic Study of Pemetrexed Compared With Pemetrexed Plus Carboplatin in Pretreated Patients With Advanced Non–Small-Cell Lung Cancer

A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Metabolism of the taxanes including nab-paclitaxel

A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Circulating Deoxyribonucleic Acid As Prognostic Marker in Non–Small-Cell Lung Cancer Patients Undergoing Chemotherapy

Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Suchergebnisse filtern